LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders.